Scinai Immunotherapeutics Ltd 最大收入來源為 Software as a Service (SaaS) and Platform as a Service (PaaS),在最近的收益報告中收入為 1,008,448,000。就地區而言,United States 是 Scinai Immunotherapeutics Ltd 的主要市場,收入為 1,014,168,000。
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.